Previous close | 23.92 |
Open | 23.90 |
Bid | 0.00 x 1800 |
Ask | 0.00 x 2200 |
Day's range | 23.85 - 24.20 |
52-week range | 21.53 - 33.09 |
Volume | |
Avg. volume | 966,233 |
Market cap | 10.496B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 40.02 |
EPS (TTM) | 0.60 |
Earnings date | N/A |
Forward dividend & yield | 0.75 (3.12%) |
Ex-dividend date | 01 Apr 2024 |
1y target est | 31.50 |
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip
This powerhouse FTSE stock has embarked on a new growth strategy that’s already showing good results, but it looks undervalued to me. The post Down 27%, but set for major growth, this hidden FTSE gem looks cheap to me appeared first on The Motley Fool UK.
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons -